Coya Therapeutics (NASDAQ:COYA) Given “Buy” Rating at BTIG Research

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating restated by equities researchers at BTIG Research in a research note issued on Tuesday, Benzinga reports. They presently have a $16.00 price objective on the stock. BTIG Research’s price objective would suggest a potential upside of 246.70% from the stock’s previous close.

COYA has been the subject of a number of other research reports. Chardan Capital restated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Friday, July 17th. Roth Capital reiterated a “buy” rating and set a $12.00 target price on shares of Coya Therapeutics in a report on Monday, August 24th. Finally, HC Wainwright reissued a “buy” rating on shares of Coya Therapeutics in a research report on Monday, August 24th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.33.

Coya Therapeutics Stock Down 0.5%

Shares of NASDAQ:COYA traded down $0.03 on Tuesday, hitting $4.62. The company had a trading volume of 101,731 shares, compared to its average volume of 181,283. The firm’s 50-day simple moving average is $4.66 and its two-hundred day simple moving average is $4.66. The firm has a market capitalization of $108.26 million, a price-to-earnings ratio of -4.29 and a beta of 0.61. Coya Therapeutics has a 1 year low of $3.71 and a 1 year high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.07. Coya Therapeutics had a negative net margin of 270.22% and a negative return on equity of 52.05%. The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million. Equities research analysts anticipate that Coya Therapeutics will post -1.34 EPS for the current year.

Institutional Trading of Coya Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Allworth Financial LP raised its holdings in shares of Coya Therapeutics by 1,200.0% during the second quarter. Allworth Financial LP now owns 13,000 shares of the company’s stock valued at $76,000 after purchasing an additional 12,000 shares during the last quarter. AXQ Capital LP purchased a new stake in Coya Therapeutics during the 2nd quarter valued at $116,000. Long Corridor Asset Management Ltd purchased a new position in shares of Coya Therapeutics in the 2nd quarter worth $227,000. ADAR1 Capital Management LLC bought a new stake in shares of Coya Therapeutics in the first quarter worth $161,000. Finally, Renaissance Technologies LLC increased its position in Coya Therapeutics by 55.4% during the first quarter. Renaissance Technologies LLC now owns 103,964 shares of the company’s stock valued at $410,000 after acquiring an additional 37,064 shares during the last quarter. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.